GlassScriptPhysician profile
Lori A Schroder
NPI 1235519760
$2,639.95
in general payments reported to CMS, 2019-2025
32 companies · $21.72 in 2025
The $21.72 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,510 · 2022: $1,023 · 2023: $71.75 · 2024: $13.24 · 2025: $21.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.54 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.08 | 2021-2022 | |
| Glaxosmithkline, LLC. | $279.51 | 2021-2025 | Trelegy Ellipta |
| Gilead Sciences, INC. | $198.32 | 2021 | |
| Celgene Corporation | $131.49 | 2021-2024 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.23 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $100.03 | 2021-2023 | Uptravi |
| Janssen Biotech, INC. | $90.94 | 2021-2022 | |
| Covis Pharma Gmbh | $72.70 | 2021-2022 | |
| Abbott Laboratories | $65.32 | 2022-2023 | Octrode |
| Advanced Respiratory, INC | $61.89 | 2021 | |
| Amgen INC. | $59.90 | 2021-2022 | |
| Grifols USA, LLC | $58.39 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $54.74 | 2021 | |
| Ironwood Pharmaceuticals, INC | $41.46 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $38.12 | 2021-2022 | |
| Redhill Biopharma INC. | $37.09 | 2021 | |
| Sanofi Pasteur INC. | $36.21 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.66 | 2021-2022 | |
| Novo Nordisk INC | $30.55 | 2021-2022 | |
| Braintree Laboratories, INC. | $29.99 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $29.79 | 2022-2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $24.34 | 2022 | |
| Ardelyx, INC. | $19.01 | 2022 | |
| Baxter Healthcare | $16.14 | 2022 | |
| Boston Scientific Corporation | $15.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.66 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.13 | 2021 | |
| Merck Sharp & Dohme LLC | $12.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.64 | 2021 | |
| Daiichi Sankyo INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Schroder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.